{"id":"W2556440321","doi":"10.1182/blood.v126.23.799.799","title":"Treatment of 11q23/MLL + AML with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; Population Health Research Institute; Hospital for Sick Children","funders":"","keywords":"Gemtuzumab ozogamicin; CD33; Internal medicine; Medicine; Myeloid leukemia; Leukemia; Oncology; Gastroenterology; Biology; CD34; Stem cell; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002688607,0.0008645485,0.001289519,0.0003150237,0.0003331651,0.0009572543,0.0006842894,0.001136023,0.001565667],"category_scores_gemma":[0.001328887,0.0003475084,0.001361943,0.0003855059,0.0007920736,0.0006078389,0.0004022219,0.002222657,0.0002598887],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001123742,"about_ca_system_score_gemma":0.001370085,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001462395,"about_ca_topic_score_gemma":0.003653841,"domain_scores_codex":[0.9990959,0.0006211711,0.00003784805,0.00007503061,0.00006809388,0.0001018765],"domain_scores_gemma":[0.9988752,0.0002915394,0.0002830719,0.00007452381,0.00005200869,0.0004236469],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9072661,0.01672512,0.0105861,0.0005088153,0.001691289,0.0001298086,0.0001827938,0.00194087,0.01013816,0.0004540372,0.003965656,0.04641114],"study_design_scores_gemma":[0.746683,0.217696,0.02696699,0.00008679632,0.001036057,0.0002089536,0.00008549355,0.001353621,0.001875419,0.0003476385,0.003629172,0.00003083788],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939551,0.002694791,0.000193318,0.0006487197,0.0001018092,0.001007809,0.0007517953,0.00003349849,0.0006132856],"genre_scores_gemma":[0.9913737,0.001931909,0.001172422,0.001139922,0.0001740974,0.001532843,0.001764149,0.00001532861,0.0008955438],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002688607,"threshold_uncertainty_score":0.01421887,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03410346710533554,"score_gpt":0.3246124944877472,"score_spread":0.2905090273824117,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}